Strategy for NMR metabolomic analysis of urine in mouse models of obesity- from sample collection to interpretation of acquired data

Journal of Pharmaceutical and Biomedical Analysis

Volumn 115, Issue , 2015, Pages 225-235

  Pelantová, Helena ^a,b   Bugáňová, Martina ^a,f   Anýž, Jiří ^c   Železná, Blanka ^d   Maletínská, Lenka ^d   Novák, Daniel ^c   Haluzík, Martin ^e   Kuzma, Marek ^a  

^a INSTITUTE OF MICROBIOLOGY   (Czech Republic)

^b PALACKÝ UNIVERSITY   (Czech Republic)

^c CZECH TECHNICAL UNIVERSITY IN PRAGUE   (Czech Republic)

^d INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

^e CHARLES UNIVERSITY   (Czech Republic)

^f INSTITUTE OF CHEMICAL TECHNOLOGY   (Czech Republic)

Author keywords

Mouse; NMR metabolomics; Obesity; Urine

Indexed keywords

CREATININE; GLUTAMATE SODIUM; PROTEIN; BIOLOGICAL MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CIRCADIAN RHYTHM; FILTRATION; FOOD INTAKE; METABOLITE; METABOLOMICS; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEAR OVERHAUSER EFFECT; OBESITY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTON NUCLEAR MAGNETIC RESONANCE; STATISTICAL ANALYSIS; URINALYSIS; ANIMAL; DISEASE MODEL; INBRED MOUSE STRAIN; LABORATORY DIAGNOSIS; MALE; METABOLISM; METABOLOME; NEWBORN; NUCLEAR MAGNETIC RESONANCE; PRINCIPAL COMPONENT ANALYSIS; PROCEDURES; URINE;

ANIMALS; ANIMALS, NEWBORN; BIOMARKERS; DATA INTERPRETATION, STATISTICAL; DISEASE MODELS, ANIMAL; MALE; METABOLOME; METABOLOMICS; MICE, INBRED STRAINS; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; OBESITY; PRINCIPAL COMPONENT ANALYSIS; SPECIMEN HANDLING;

EID: 84938874009     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2015.06.036     Document Type: Article

References (56)

1. Danaei G., Finucane M.M., Lu Y., Singh G.M., Cowan M.J., Paciorek C.J., et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2. 7 million participants. Lancet 2011, 378:31-40.
2. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes - Estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
3. Takahara M., Shimomura I. Metabolic syndrome and lifestyle modification. Rev. Endocrinol. Metab. Disord. 2014, 15:317-327.
4. Kannel W., Dawber T., Kagan A., Revotskie N., Stokes J. Factors of risk in the development of coronary heart disease - six year follow-up experience the Framingham Study. Ann. Intern. Med. 1961, 55:33-50.
5. Salek R.M., Maguire M.L., Bentley E., Rubtsov D.V., Hough T., Cheeseman M., et al. A metabolomic comparison of urinary changes in type 2 diabetes in mouse, rat, and human. Physiol. Genomics 2007, 29:99-108.
6. Connor S.C., Hansen M.K., Corner A., Smith R.F., Ryan T.E. Integration of metabolomics and transcriptomics data to aid biomarker discovery in type 2 diabetes. Mol. Biosyst. 2010, 6:909-921.
7. Griffin J.L. Understanding mouse models of disease through metabolomics. Curr. Opin. Chem. Biol. 2006, 10:309-315.
8. Kanasaki K., Koya D. Biology of obesity: lessons from animal models of obesity. J. Biomed. Biotechnol. 2011, 2011. article ID 197636.
9. Butler A.A., Cone R.D. Knockout models resulting in the development of obesity. Trends Genet. 2001, 17:S50-S54.
10. Carroll L., Voisey J., van Daal A. Mouse models of obesity. Clin. Dermatol. 2004, 22:345-349.
11. Lutz T.A., Woods S.C. Overview of animal models of obesity. Curr. Protoc. Pharmacol. 2012, Chapter 5 Unit 5.61.
12. Buettner R., Schölmerich J., Bollheimer L.C. High-fat diets: modeling the metabolic disorders of human obesity in rodents. Obesity 2007, 15:798-808.
13. Jung J.-Y., Kim I.-Y., Kim Y.-N., Kim J.-S., Shin J.-H., Jang Z.-H., et al. 1H NMR-based metabolite profiling of diet-induced obesity in a mouse model. BMB Rep. 2012, 45:419-424.
14. Kim I.Y., Jung J., Jang M., Ahn Y.G., Shin J.H., Choi J.W., et al. 1H NMR-based metabolomic study on resistance to diet-induced obesity in AHNAK knock-out mice. Biochem. Biophys. Res. Commun. 2010, 403:428-434.
15. Shearer J., Duggan G., Weljie A., Hittel D.S., Wasserman D.H., Vogel H.J. Metabolomic profiling of dietary-induced insulin resistance in the high fat-fed C57BL/6J mouse. Diabetes. Obes. Metab 2008, 10:950-958.
16. Nagata M., Suzuki W., Iizuka S., Tabuchi M., Maruyama H., Takeda S., et al. Type 2 diabetes mellitus in obese mouse model induced by monosodium glutamate. Exp. Anim. 2006, 55:109-115.
17. Smolinska A., Blanchet L., Buydens L.M.C., Wijmenga S.S. NMR and pattern recognition methods in metabolomics: from data acquisition to biomarker discovery: a review. Anal. Chim. Acta 2012, 750:82-97.
18. Duarte I.F., Diaz S.O., Gil A.M. NMR metabolomics of human blood and urine in disease research. J. Pharm. Biomed. Anal. 2014, 93:17-26.
19. Emwas A.-H.M., Salek R.M., Griffin J.L., Merzaban J. NMR-based metabolomics in human disease diagnosis: applications, limitations, and recommendations. Metabolomics 2013, 9:1048-1072.
20. Beckonert O., Keun H.C., Ebbels T.M.D., Bundy J., Holmes E., Lindon J.C., et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat. Protoc. 2007, 2:2692-2703.
21. Emwas A.-H., Luchinat C., Turano P., Tenori L., Roy R., Salek R.M., et al. Standardizing the experimental conditions for using urine in NMR-based metabolomic studies with a particular focus on diagnostic studies: a review. Metabolomics 2014, 10.1007/s11306-014-0746-7.
22. Mckay R.T. How the 1D-NOESY suppresses solvent signal in metabonomics NMR spectroscopy: an examination of the pulse sequence components and evolution. Concepts Magn. Reson. Part A 2011, 38A:197-220.
23. Zhou Y., Rui L. Major urinary protein regulation of chemical communication and nutrient metabolism. Vitamins and Hormones 83 2010, 151-163. Elsevier Inc., Amsterdam. G. Litwack (Ed.).
24. Carr H., Purcell E. Effects of diffusion on free precession in nuclear magnetic resonance experiments. Phys. Rev. 1954, 94:630-638.
25. Meiboom S., Gill D. Modified spin-echo method for measuring nuclear relaxation times. Rev. Sci. Instrum. 1958, 29:688-691.
26. Aue W.P., Karhan J., Ernst R.R. Homonuclear broad band decoupling and two-dimensional J-resolved NMR spectroscopy. J. Chem. Phys. 1976, 64:4226-4227.
27. Ludwig C., Viant M.R. Two-dimensional J-resolved NMR spectroscopy: review of a key methodology in the metabolomics toolbox. Phytochem. Anal. 2010, 21:22-32.
28. Thrippleton M.J., Edden R.A.E., Keeler J. Suppression of strong coupling artefacts in J-spectra. J. Magn. Reson. 2005, 174:97-109.
29. Parsons H.M., Ludwig C., Viant M.R. Line-shape analysis of J-resolved NMR spectra: application to metabolomics and quantification of intensity errors from signal processing and high signal congestion. Magn. Reson. Chem. 2009, 47(Suppl 1):S86-S95.
30. Ross A., Schlotterbeck G., Dieterle F., Senn H. NMR spectroscopy techniques for application to metabonomics. Handb. Metabonomics Metabolomics 2007, 55-112. Elsevier Science B.V., Amsterdam. J.C. Lindon, J.K. Nicholson, E. Holmes (Eds.).
31. Dieterle F., Ross A., Schlotterbeck G., Senn H. Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics. Anal. Chem. 2006, 78:4281-4290.
32. Zuppi C., Messana I., Forni F., Rossi C., Pennacchietti L., Ferrari F., et al. 1H NMR spectra of normal urines: reference ranges of the major metabolites. Clin. Chim. Acta. 1997, 265:85-97.
33. Bouatra S., Aziat F., Mandal R., Guo A.C., Wilson M.R., Knox C., et al. The human urine metabolome. PLoS One 2013, 8:e73076.
34. Saude E.J., Adamko D., Rowe B.H., Marrie T., Sykes B.D. Variation of metabolites in normal human urine. Metabolomics 2007, 3:439-451.
35. Saude E., Sykes B. Urine stability for metabolomic studies: effects of preparation and storage. Metabolomics 2007, 3:19-27.
36. Calvani R., Brasili E., Praticò G., Capuani G., Tomassini A., Marini F., et al. Fecal and urinary NMR-based metabolomics unveil an aging signature in mice. Exp. Gerontol. 2014, 49:5-11.
37. Portilla D., Li S., Nagothu K.K., Megyesi J., Kaissling B., Schnackenberg L., et al. Metabolomic study of cisplatin-induced nephrotoxicity. Kidney Int. 2006, 69:2194-2204.
38. Olney J.W. Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science 1969, 164:719-721.
39. Matyšková R., Maletínská L., Maixnerová J., Pirník Z., Kiss A. Comparison of the obesity phenotypes related to monosodium glutamate effect on arcuate nucleus and/or the high fat diet feeding in C57BL/6 and NMRI mice. Physiol. Behav. 2008, 57:727-734.
40. Hernández-Bautista R.J., Alarcón-Aguilar F.J., Del Escobar-Villanueva M.C., Almanza-Pérez J.C., Merino-Aguilar H., Fainstein M.K., et al. Biochemical alterations during the obese-aging process in female and male monosodium glutamate (MSG)-treated mice. Int. J. Mol. Sci. 2014, 15:11473-11494.
41. Djazayery A., Miller D.S., Stock M.J. Energy balances in obese mice. Ann. Nutr. Metab. 1979, 23:357-367.
42. Maletínská L., Toma R.S., Pirnik Z., Kiss A., Slaninová J., Haluzík M., et al. Effect of cholecystokinin on feeding is attenuated in monosodium glutamate obese mice. Regul. Pept. 2006, 136:58-63.
43. Jolliffe I.T. Principal Component Analysis 2002, xxix:487. Springer, New York, ISBN 0387954422. 2nd ed.
44. MATLAB version 8.1.0.604 (R2013a). Natick, Massachusetts: The MathWorks Inc., 2013.
45. R Core Team R: A Language and Environment for Statistical Computing 2015, R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/.
46. G.D. Djira, M. Hasler, D. Gerhard, F. Schaarschmidt (2012). mratios: Inferences for ratios of coefficients in the general linear model. R package version 1.3.17. http://CRAN.R-project.org/package=mratios.
47. Xie B., Waters M.J., Schirra H.J. Investigating potential mechanisms of obesity by metabolomics. J. Biomed. Biotechnol. 2012, 2012. article ID 805683.
48. Lanza I.R., Zhang S., Ward L.E., Karakelides H., Raftery D., Nair K.S. Quantitative metabolomics by H NMR and LC-MS/MS confirms altered metabolic pathways in diabetes. PLoS One 2010, 5:e10538.
49. Messana I., Forni F., Ferrari F., Rossi C., Giardina B., Zuppi C. Proton nuclear magnetic resonance spectral profiles of urine in type II diabetic patients. Clin. Chem. 1998, 44:1529-1534.
50. Gavaghan C.L., Wilson I.D., Nicholson J.K. Physiological variation in metabolic phenotyping and functional genomic studies: use of orthogonal signal correction and PLS-DA. FEBS Lett. 2002, 530:191-196.
51. Williams R.E., Lenz E.M., Evans J.A., Wilson I.D., Granger J.H., Plumb R.S., et al. A combined 1H NMR and HPLC-MS-based metabonomic study of urine from obese (fa/fa) Zucker and normal Wistar-derived rats. J. Pharm. Biomed. Anal. 2005, 38:465-471.
52. Bollard M.E., Holmes E., Lindon J.C., Mitchell S.C., Branstetter D., Zhang W., et al. Investigations into biochemical changes due to diurnal variation and estrus cycle in female rats using high-resolution 1H NMR spectroscopy of urine and pattern recognition. Anal. Biochem. 2001, 295:194-202.
53. Leo G.C., Darrow A.L. NMR-based metabolomics of urine for the atherosclerotic mouse model using apolipoprotein-E deficient mice. Magn. Reson. Chem. 2009, 47:S20-S25. Suppl 1.
54. Zhou Y., Jiang L., Rui L. Identification of MUP1 as a regulator for glucose and lipid metabolism in mice. J. Biol. Chem. 2009, 284:11152-11159.
55. Hui X., Zhu W., Wang Y., Lam K.S.L., Zhang J., Wu D., et al. Major urinary protein-1 increases energy expenditure and improves glucose intolerance through enhancing mitochondrial function in skeletal muscle of diabetic mice. J. Biol. Chem. 2009, 284:14050-14057.
56. Giller K., Huebbe P., Doering F., Pallauf K., Rimbach G. Major urinary protein 5, a scent communication protein, is regulated by dietary restriction and subsequent re-feeding in mice. Proc. Biol. Sci 2013, 280. article ID 20130101.